<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB807275-D239-41F7-9C97-05ADC965F4E7"><gtr:id>EB807275-D239-41F7-9C97-05ADC965F4E7</gtr:id><gtr:name>Spanish National Centre for Biotechnology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB807275-D239-41F7-9C97-05ADC965F4E7"><gtr:id>EB807275-D239-41F7-9C97-05ADC965F4E7</gtr:id><gtr:name>Spanish National Centre for Biotechnology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5F11D1FF-1F2A-462B-BAD2-856965BB83AC"><gtr:id>5F11D1FF-1F2A-462B-BAD2-856965BB83AC</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Ley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117584209"><gtr:id>513F512A-B186-4671-A8C4-2E5F2F8E42E9</gtr:id><gtr:title>Analysis of the regulation and function of NF- B1 p105, TPL-2 and ABIN-2 in immune responses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117584209</gtr:grantReference><gtr:abstractText>Rheumatoid arthritis (RA) is a common human autoimmune disease, which is characterized by chronic inflammation of the synovial joints and progressive destruction of cartilage and bone. Localized inflammatory responses, in this case in blood vessel walls, are similarly important in atherosclerosis, a leading cause of morbidity and mortality in industrialized countries. An understanding of the mechanism by which inflammatory responses are controlled is important for development of new therapies for these major diseases.The initiation of inflammatory responses depends on the NF-?B family of intracellular proteins, which regulate the expression of multiple genes that are switched on in both RA and atherosclerosis. The activation of NF-?B involves several distinct signalling pathways and my laboratory concentrates on one of these that is dependant on the protein NF-B1 p105. Our recent work has shown that this controls not only the activation of NF-B proteins but also of another signalling protein, TPL-2. We are currently investigating in more detail how p105 regulates TPL-2 activation and how both of these proteins control immune and inflammatory responses. It is hoped that our work might identify novel targets for the development of anti-inflammatory drugs for the treatment of inflammatory diseases such as RA and atherosclerosis.</gtr:abstractText><gtr:technicalSummary>Objectives: Research in my laboratory concentrates on the role of signal-induced proteolysis of the NF-?B inhibitory protein NF-?B1 p105 in immune responses and also the regulation and function of the p105-associated proteins, TPL-2 (COT) kinase and ABIN-2. This works may identify novel targets for pharmacological manipulation of the immune system in inflammatory diseases such rheumatoid arthritis and atherosclerosis. Methodology: My research involves a variety of molecular biology techniques, analytical and preparative protein chemistry, in vitro cell culture and confocal microscopy. Summary: My major research achievements during the last five years are summarized below: Demonstration that NF-?B1 p105 negatively regulates the MEK kinase activity of TPL-2 Demonstration that TLR4 activation of ERK MAP kinase in macrophages is dependent on IKK-triggered proteolysis of NF-?B1 p105Demonstration that ABIN-2 forms a ternary complex with NF-?B1 p105 / TPL-2 and is required to maintain TPL-2 protein stability Demonstration that ABIN-2 is required for optimal activation of the TPL-2 / ERK signalling pathway in innate immune responses</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1992-09-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>9278035</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Crick-GSK LinkLabs</gtr:department><gtr:description>Characterisation of the TPL-2/NF-kB1 p105/CARD14 complex</gtr:description><gtr:id>6D75F8B0-CFE5-45FC-AA09-AB41C2B91B4C</gtr:id><gtr:impact>None yet...</gtr:impact><gtr:outcomeId>58c7e17f06f475.90440234-1</gtr:outcomeId><gtr:partnerContribution>Funded 3-year Post-Doctoral Research Associate to work on the characterisation of the TPL-2/NF-kB1 p105/ABIN-2 complex.</gtr:partnerContribution><gtr:piContribution>Knowledge about the regulation and function of the TPL-2 complex in inflammation. Provided purified TPL-2/NF-kB1 p105/ABIN-2 complex for enzyme kinetic experiments.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TPL-2 and lymphoma / leukaemia</gtr:description><gtr:id>DC333790-FCDC-4BAF-9B97-AB07F4BC4130</gtr:id><gtr:impact>17324460</gtr:impact><gtr:outcomeId>26423890FCA-1</gtr:outcomeId><gtr:piContribution>Initiated project after discussion with Ming Du</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TPL-2 complex production</gtr:description><gtr:id>F58D82D0-1362-4B0E-8625-2D466FBCD130</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>P1mGg5shcj3-1</gtr:outcomeId><gtr:partnerContribution>&amp;gt; Developed assays to measure catalytic activity of TPL-2</gtr:partnerContribution><gtr:piContribution>&amp;gt; Developed method for production of TPL-2/p105/ABIN-2 complex</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Proteomics Laboratory, LRI</gtr:department><gtr:description>Regulation of TNF production by TPL-2</gtr:description><gtr:id>F309A34A-BE31-4599-9C9E-C7DD93526B14</gtr:id><gtr:impact>18187448</gtr:impact><gtr:outcomeId>2C749B2A3B7-2</gtr:outcomeId><gtr:partnerContribution>Mass spectrometric analysis of protein phosphorylation</gtr:partnerContribution><gtr:piContribution>Provided data showing the effects of TPL-2 deficiency on TNF production by macrophages.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Regulation of TNF production by TPL-2</gtr:description><gtr:id>1BCCDA08-3E8E-4F42-8B15-D4E6A55F41EB</gtr:id><gtr:impact>18187448</gtr:impact><gtr:outcomeId>2C749B2A3B7-1</gtr:outcomeId><gtr:partnerContribution>Mass spectrometric analysis of protein phosphorylation</gtr:partnerContribution><gtr:piContribution>Provided data showing the effects of TPL-2 deficiency on TNF production by macrophages.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Regulation of IFNb production by TPL-2.</gtr:description><gtr:id>A679AC8F-65D0-43D1-8D11-23C6719FC9F1</gtr:id><gtr:impact>19667062</gtr:impact><gtr:outcomeId>D86F6611F5F-1</gtr:outcomeId><gtr:piContribution>Generated some of initial data showing that the TPL-2/ERK pathway regulated IFNb production.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thomas Jefferson University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Arrestin-2 regulation of NF-kB1 p105</gtr:description><gtr:id>D943BAA1-9F75-407A-AD23-5565D563653F</gtr:id><gtr:impact>16980301</gtr:impact><gtr:outcomeId>BA8C9A07D3A-1</gtr:outcomeId><gtr:piContribution>Provided advice on the regulation of the TPL-2/ERK signalling pathway.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spanish National Centre for Biotechnology</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Department of Immunology and Oncology</gtr:department><gtr:description>p38 gamma/delta regulation of TPL-2 signalling</gtr:description><gtr:id>6913D83C-A590-4993-945C-4B3B0537B507</gtr:id><gtr:impact>Risco, A., Del Fresno, C., Mambol, A., Alsina-Beauchamp, D. Mackenzie, K. F., Yang, H. T., Barber, D. F., Morcelle, C., Arthur, J. S., Ley, S. C., Ardavin, C., Cuenda, A. (2012) p38? and p38d kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc. Natl. Acad. Sci. USA 109, 11200 - 11205.</gtr:impact><gtr:outcomeId>oQG92S3Sj2Y-1</gtr:outcomeId><gtr:partnerContribution>&amp;gt; Demonstrated requirment for p38 gamma/delta to maintain steady-state levels of TPL-2 in myeloid cells</gtr:partnerContribution><gtr:piContribution>&amp;gt; Advice on TPL-2 signalling in macrophages and dendritic cells
&amp;gt; Retroviral expression of p38 gamma in Tpl2-/- macrophages</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Analysis of Abin2 knockout mice</gtr:description><gtr:id>2A8CA77C-EA0D-41EF-AD3E-0C869308E958</gtr:id><gtr:impact>16633345</gtr:impact><gtr:outcomeId>12C69E237D2-1</gtr:outcomeId><gtr:piContribution>Analysis of Abin2 knockout mice.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HIF and NF-kB</gtr:description><gtr:id>46D9A9CF-1A31-464C-9E4E-D7D4D6B91344</gtr:id><gtr:impact>17003112</gtr:impact><gtr:outcomeId>CDBBCBCAAEC-1</gtr:outcomeId><gtr:piContribution>Provided advice on NF-kB signalling and reagents for experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Production of Abin2 knockout mice</gtr:description><gtr:id>03570D93-C570-459D-A9CC-98FDB6423FA3</gtr:id><gtr:impact>16633345</gtr:impact><gtr:outcomeId>06611CC9870-1</gtr:outcomeId><gtr:piContribution>Generation and analysis of ABIN-2 deficient mice.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Production of Nfkb1[SS/AA] knockin mice.</gtr:description><gtr:id>16F1E6D8-11BD-4AE7-8982-D29D23DAFC9C</gtr:id><gtr:impact>19060899</gtr:impact><gtr:outcomeId>D99255FE21B-1</gtr:outcomeId><gtr:piContribution>Generated and analysed Nfkb1[SS/AA] knockin mice.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>25046</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Funding</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>75DC12F7-1B26-4013-A4C4-8B278885A9EE</gtr:id><gtr:outcomeId>4EB3FBAFBE60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>168725</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARC Project Grant</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>8E3A6127-C1F4-4E63-934C-7550F7C99B65</gtr:id><gtr:outcomeId>64B454EF9820</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>158751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Project Grant 2007</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>48D567A2-39F3-4F9B-996C-F620E3D2A088</gtr:id><gtr:outcomeId>2A0DCA5E6300</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>119000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development Gap Funding</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>48803837-EE8B-47EA-8ED1-297FE0DD1A78</gtr:id><gtr:outcomeId>a17SghqCsKM</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a new method for production of recombinant proteins in human HEK293 cells. This involves co-expressing Ebola virus VP35, which blocks DNA plasmid activation of PKR, increasing protein translation and substantially increasing protein yield.</gtr:description><gtr:id>2D740EF2-7837-4DA5-B530-5B6DD6DED62B</gtr:id><gtr:impact>This new method has allowed my group to produce sufficient TPL-2 complex to carry out a high throughput screen for TPL-2 inhibitors with MRC Technology.</gtr:impact><gtr:outcomeId>mCDzsd7fSHT</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VP35</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B72D7D76-E0FB-4208-AE4F-AD8508753BBF</gtr:id><gtr:title>BAFF activation of the ERK5 MAP kinase pathway regulates B cell survival.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e60855d1b32b50279f7ef43c7b33f222"><gtr:id>e60855d1b32b50279f7ef43c7b33f222</gtr:id><gtr:otherNames>Jacque E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>56d989f649a6f6.62633208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C227A893-D6D4-459B-B456-9F05D2D88B81</gtr:id><gtr:title>IKK-induced NF-?B1 p105 proteolysis is critical for B cell antibody responses to T cell-dependent antigen.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e60855d1b32b50279f7ef43c7b33f222"><gtr:id>e60855d1b32b50279f7ef43c7b33f222</gtr:id><gtr:otherNames>Jacque E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>546216270fd091.30646751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C584454-82DF-48C2-9E69-E48C7DC9D6B9</gtr:id><gtr:title>I?B kinase regulation of the TPL-2/ERK MAPK pathway.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10fdb4a8dae359ccc3c7597359714252"><gtr:id>10fdb4a8dae359ccc3c7597359714252</gtr:id><gtr:otherNames>Gantke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_15403_23_22435554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F3275A4-C778-4D1A-847B-1CA50F6A4BC7</gtr:id><gtr:title>Priming IKK? kinase for action.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32d52ec15a7dc5021c772739b12c8ec9"><gtr:id>32d52ec15a7dc5021c772739b12c8ec9</gtr:id><gtr:otherNames>Ley SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>54621605863a70.67773548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B8AD99F-3624-4F44-BF1C-D7DBA70B357C</gtr:id><gtr:title>Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64669c469bb85c14af6967c259e5623b"><gtr:id>64669c469bb85c14af6967c259e5623b</gtr:id><gtr:otherNames>Sriskantharajah S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15403_23_24639351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00CA2380-418B-4B45-B818-263C6E5728F0</gtr:id><gtr:title>TPL-2-ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a567e445f45cd9579c85c397f97b850e"><gtr:id>a567e445f45cd9579c85c397f97b850e</gtr:id><gtr:otherNames>McNab FW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>546216fdda3d75.14239410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2916CD66-FC88-4D19-BE87-D1CFA49F2E79</gtr:id><gtr:title>NF-?B1 inhibits TLR-induced IFN-? production in macrophages through TPL-2-dependent ERK activation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70bc412b1ff07d0fd9db666ee9f98b16"><gtr:id>70bc412b1ff07d0fd9db666ee9f98b16</gtr:id><gtr:otherNames>Yang HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15403_23_21217011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF40535F-B7AF-4A76-9B7B-6C7CC82A059A</gtr:id><gtr:title>I?B kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f6079846d793d49673b6e7837db43ca"><gtr:id>8f6079846d793d49673b6e7837db43ca</gtr:id><gtr:otherNames>Ben-Addi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>546216be3a6919.93058895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4E9F78B-84B5-4FAE-8F70-F70514AC3A47</gtr:id><gtr:title>A20 inactivation in ocular adnexal MALT lymphoma.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33cc2aea45006dfedacbe3c068c8dcd8"><gtr:id>33cc2aea45006dfedacbe3c068c8dcd8</gtr:id><gtr:otherNames>Bi Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_15403_23_22207688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79BD1F6A-5674-43D2-A8AA-90AF6C38A8C3</gtr:id><gtr:title>I?B kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa31f52c9330589808ede67fc6e93259"><gtr:id>fa31f52c9330589808ede67fc6e93259</gtr:id><gtr:otherNames>Roget K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>pm_15403_23_22988300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3246D65-6DC7-4118-B664-A1920D0B7ABF</gtr:id><gtr:title>ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e878087558987d34858c4edccf0f81"><gtr:id>68e878087558987d34858c4edccf0f81</gtr:id><gtr:otherNames>Gao L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15403_23_21885437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EE80587-B171-4034-852A-5A48CE2CC214</gtr:id><gtr:title>p38? and p38d kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91358f22979804e45f2844bd852fb97d"><gtr:id>91358f22979804e45f2844bd852fb97d</gtr:id><gtr:otherNames>Risco A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15403_23_22733747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A9354E2-C91D-4315-A9B3-68E92E7AD2F2</gtr:id><gtr:title>NF-?B signaling mediates homeostatic maturation of new T cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78620a0072abfc94b6484167862045"><gtr:id>8e78620a0072abfc94b6484167862045</gtr:id><gtr:otherNames>Silva A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5462166c1edd43.05745054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5BE8570-8F57-4E8A-93BB-BC5ADB8B96BC</gtr:id><gtr:title>Ebola virus VP35 induces high-level production of recombinant TPL-2-ABIN-2-NF-?B1 p105 complex in co-transfected HEK-293 cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10fdb4a8dae359ccc3c7597359714252"><gtr:id>10fdb4a8dae359ccc3c7597359714252</gtr:id><gtr:otherNames>Gantke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_15403_23_23557442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E03FA5A-A6F3-4950-A039-3B95C99799FF</gtr:id><gtr:title>Regulation and function of TPL-2, an I?B kinase-regulated MAP kinase kinase kinase.</gtr:title><gtr:parentPublicationTitle>Cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10fdb4a8dae359ccc3c7597359714252"><gtr:id>10fdb4a8dae359ccc3c7597359714252</gtr:id><gtr:otherNames>Gantke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1001-0602</gtr:issn><gtr:outcomeId>pm_15403_23_21135874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5114E4FC-1DF5-4F1F-BD19-A5391A4D0916</gtr:id><gtr:title>Coordinate regulation of TPL-2 and NF-?B signaling in macrophages by NF-?B1 p105.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70bc412b1ff07d0fd9db666ee9f98b16"><gtr:id>70bc412b1ff07d0fd9db666ee9f98b16</gtr:id><gtr:otherNames>Yang HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>pm_15403_23_22733995</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117584209</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>